Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)

Mark A. Socinski,Mustafa Özgüroğlu,Augusto Villegas,Davey Daniel,David Vicente,Shuji Murakami,Rina Hui,Jhanelle E. Gray,Keunchil Park,Mark Vincent,Helen Mann,Michael Newton,Phillip A. Dennis,Scott J. Antonia

Clinical Lung Cancer（2021）

引用 18|浏览0

暂无评分

摘要

•The PACIFIC trial was not designed to assess outcomes in elderly patients.•Outcomes were assessed in subgroups defined by a post-hoc 70-year age threshold.•PFS and OS benefit favored durvalumab vs. placebo regardless of age.•Durvalumab was well tolerated compared with placebo in both age groups.•Small group sizes and imbalances in baseline factors prevents robust conclusions.

查看译文

关键词

Exploratory analysis,Immune-checkpoint inhibitors,Patient-reported outcomes,Survival,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要